Sanofi, Long-Time Leader In Diabetes, Is Exiting Diabetes Research
The company's decision to exit diabetes research is not necessarily surprising given the development and commercial challenges in the therapeutic area, but it's not insignificant either.
You may also be interested in...
The company released an annual pricing report, showing that Sanofi's US average net prices declined for the fifth year in a row.
Mylan is the first to launch insulin glargine competition in both a vial and pre-filled pen, joining Eli Lilly's Basaglar pen.
Sanofi to sell most of its Regeneron stake, with much of it being re-purchased by Regeneron, but both stressed the move would not hurt their long established and very profitable drug-development collaboration.